Qualigen Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed Jul 21, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Jul 21, 2025
FFR$0.91+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Item 6. | Exhibits |
|---|
| Exhibit Number | Description |
| 31.1 | Certification of Kevin Richardson II, Chief Executive Officer of Qualigen Therapeutics, Inc., Inc., pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. |
| 31.2 | Certification of Kevin Richardson II, Chief Financial Officer of Qualigen Therapeutics, Inc., Inc., pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. |
| 32.1 | Certification of Kevin Richardson II, Chief Executive Officer of Qualigen Therapeutics, Inc., pursuant to 18 U.S.C. Section 1350. |
| 32.2 | Certification of Kevin Richardson II, Chief Financial Officer of Qualigen Therapeutics, Inc., Inc., pursuant to 18 U.S.C. Section 1350. |
| 101 | The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL: (i) Consolidated Statements of Cash Flows, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Balance Sheets, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL (included as Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| July 21, 2025 | QUALIGEN THERAPEUTICS, INC. (REGISTRANT) | |
|---|---|---|
| By: | /s/ Kevin Richardson II | |
| Name: | Kevin Richardson II | |
| Title: | Chief Financial Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.